Literature DB >> 15022032

Salivary caffeine metabolic ratio in alcohol-dependent subjects.

Veerapol Kukongviriyapan1, Laddawan Senggunprai, Auemduan Prawan, Danu Gaysornsiri, Upa Kukongviriyapan, Jareerat Aiemsa-Ard.   

Abstract

OBJECTIVES: To determine whether caffeine (CA) clearance and salivary paraxanthine (PX)/CA ratio were altered in alcohol-dependent subjects and also whether salivary PX/CA ratio was affected by arylamine-N-acetylation 2 ( NAT-2) genotypes.
METHODS: Of 30 male individuals recruited in assessing PX/CA ratio and CA clearance by ingestion of CA, 13 were healthy control, 10 were alcohol-dependent subjects with abnormal liver function tests and 7 were alcohol-dependent subjects with normal liver function. CA and PX levels were analysed by means of high-performance liquid chromatography. CA clearance was calculated from concentrations of CA in saliva at various time intervals. In another study, PX/CA ratios were assessed in 46 healthy male subjects. Their NAT2 status was genotyped using polymerase chain reaction with restriction fragment length polymorphism assay.
RESULTS: Salivary CA clearance was well correlated with plasma and salivary PX/CA ratios in a wide range of the clearance. Correlation between salivary PX/CA ratio and CA clearance was considered high from the first hour after CA ingestion and continued so for at least 9 h (r=0.94-0.96, P<0.001). PX/CA ratio in saliva was also well correlated with plasma PX/CA ratio (r=0.98, P<0.001). Salivary CA clearance in the control group was significantly higher than that of patients with abnormal liver function tests, i.e. (mean+/-SEM; 95% confidence limits; l/h/kg) 0.094+/-0.013 (0.064-0.124) and 0.044+/-0.019 (0.002-0.091), respectively, and not different from that of patients with normal liver function tests [0.107+/-0.017 (0.066-0.149)]. Similarly, the same is true for PX/CA ratio. NAT2 genotype status did not apparently affect PX/CA ratio.
CONCLUSION: Saliva-based PX/CA ratio was a convenient and robust method for assessment of CYP1A2 activity and liver function and it was shown to be altered in alcohol-dependent patients with mild abnormal liver function test.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15022032     DOI: 10.1007/s00228-004-0734-3

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  26 in total

1.  Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva.

Authors:  U Fuhr; K L Rost
Journal:  Pharmacogenetics       Date:  1994-06

2.  Caffeine clearance and biotransformation in patients with chronic liver disease.

Authors:  N R Scott; D Stambuk; J Chakraborty; V Marks; M Y Morgan
Journal:  Clin Sci (Lond)       Date:  1988-04       Impact factor: 6.124

3.  Salivary clearance and urinary metabolic pattern of caffeine in healthy children and in pediatric patients with hepatocellular diseases.

Authors:  A el-Yazigi; S Shabib; S al-Rawithi; A Yusuf; E S Legayada; A al-Humidan
Journal:  J Clin Pharmacol       Date:  1999-04       Impact factor: 3.126

4.  A urinary metabolite ratio that reflects systemic caffeine clearance.

Authors:  M E Campbell; S P Spielberg; W Kalow
Journal:  Clin Pharmacol Ther       Date:  1987-08       Impact factor: 6.875

5.  Overnight salivary caffeine clearance: a liver function test suitable for routine use.

Authors:  G Jost; A Wahlländer; U von Mandach; R Preisig
Journal:  Hepatology       Date:  1987 Mar-Apr       Impact factor: 17.425

6.  Fluvoxamine is a potent inhibitor of cytochrome P4501A2.

Authors:  K Brøsen; E Skjelbo; B B Rasmussen; H E Poulsen; S Loft
Journal:  Biochem Pharmacol       Date:  1993-03-24       Impact factor: 5.858

7.  The effect of liver disease on urine caffeine metabolite ratios.

Authors:  C P Denaro; M Wilson; P Jacob; N L Benowitz
Journal:  Clin Pharmacol Ther       Date:  1996-06       Impact factor: 6.875

8.  Effect of interferon alpha-ribavirin bitherapy on cytochrome P450 1A2 and 2D6 and N-acetyltransferase-2 activities in patients with chronic active hepatitis C.

Authors:  Laurent Becquemont; Olivier Chazouilleres; Lawrence Serfaty; Jean Marie Poirier; Franck Broly; Patrice Jaillon; Raoul Poupon; Christian Funck-Brentano
Journal:  Clin Pharmacol Ther       Date:  2002-06       Impact factor: 6.875

9.  Chloroquine modulation of specific metabolizing enzymes activities: investigation with selective five drug cocktail.

Authors:  A Adedoyin; R F Frye; K Mauro; R A Branch
Journal:  Br J Clin Pharmacol       Date:  1998-09       Impact factor: 4.335

10.  Arylamine N-acetyltransferase-2 genotypes in the Thai population.

Authors:  Veerapol Kukongviriyapan; Auemduan Prawan; Wichittra Tassaneyakul; Jareerat Aiemsa-Ard; Benjamart Warasiha
Journal:  Br J Clin Pharmacol       Date:  2003-03       Impact factor: 4.335

View more
  3 in total

Review 1.  Alternative Sampling Strategies for Cytochrome P450 Phenotyping.

Authors:  Pieter M M De Kesel; Willy E Lambert; Christophe P Stove
Journal:  Clin Pharmacokinet       Date:  2016-02       Impact factor: 6.447

2.  Comparison of Caffeine and d-amphetamine in Cocaine-Dependent Subjects: Differential Outcomes on Subjective and Cardiovascular Effects, Reward Learning, and Salivary Paraxanthine.

Authors:  Scott D Lane; Charles E Green; Joy M Schmitz; Nuvan Rathnayaka; Wendy B Fang; Sergi Ferré; F Gerard Moeller
Journal:  J Addict Res Ther       Date:  2014

Review 3.  Pharmacokinetics of Caffeine: A Systematic Analysis of Reported Data for Application in Metabolic Phenotyping and Liver Function Testing.

Authors:  Jan Grzegorzewski; Florian Bartsch; Adrian Köller; Matthias König
Journal:  Front Pharmacol       Date:  2022-02-25       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.